Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy.
With more than 3 million proven infections and 100.000 associated deaths in Italy, the COVID-19 pandemic poses extraordinary challenges to health-care professionals and especially to those caring for patients with haematologic malignancies (1-2). Given the multiple immune defects characterizing...
Saved in:
| Main Authors: | Stefano Molica, Paolo Sportoletti, Nicola Di Renzo, Pellegrino Musto, Fabrizio Pane, Francesco Di Raimondo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2021-06-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://www.mjhid.org/index.php/mjhid/article/view/4613 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Venetoclax-Based Regimens in CLL: Immunoglobulin G Levels, Absolute Neutrophil Counts, and Infectious Complications
by: Wojciech Szlasa, et al.
Published: (2025-06-01) -
SUCCESSFUL LONG-TERM REMISSION IN AGGRESSIVE YOUNG-ONSET CHRONIC LYMPHOCYTIC LEUKEMIA WITH IBRUTINIB AND VENETOCLAX: A DECADE-LONG CASE STUDY
by: Naciye Nur Tozluklu, et al.
Published: (2024-12-01) -
Efficacy and safety of venetoclax in relapsed/refractory chronic lymphocytic leukemia in Russia routine clinical practice
by: E. A. Dmitrieva, et al.
Published: (2024-09-01) -
Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01) -
Acquired Hemophilia A successfully treated with rituximab
by: Giovanni D'Arena, et al.
Published: (2015-02-01)